Floatz logo

Cyclophosphamide

Multiple Sclerosis, Chronic Progressive

Bruce CreeSmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Multiple Sclerosis, Chronic Progressive cohort.

Asset / SponsorPhaseRating
D-thioctic acid
Rebecca Spain
Phase 2/3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Centre Hospitalier de PAU
Phase 2B
Masitinib
AB Science
Phase 3B
Nurown Msc-Ntf Cells
Brainstorm-Cell Therapeutics
Phase 2B
N-Acetyl-L-Cysteine
University of California, San Francisco
Phase 2B

View all 29 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →